We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sensitive Technique Detects Colorectal Cancer in Tissue Samples

By LabMedica International staff writers
Posted on 13 Jul 2015
A new sensitive technique has been developed that is capable of detecting colorectal cancer in tissue samples and the method could one day be used in clinical settings for the early diagnosis of colorectal cancer.

The technique measures the activity of a protein called DNA (cytosine-5)-methyltransferase 1(DNMT1) as a possible indicator of a cancerous transformation. More...
DNMT1 is a methyltransferase, an enzyme responsible for DNA methylation which is the addition of a methyl group to one of DNA's bases.

Chemists at the California Institute of Technology (Pasadena, CA, USA) devised an electrochemical platform to measure the activity of DNMT1 in crude tissue samples, those that contain all of the material from a tissue, not just DNA or ribonucleic acid (RNA), for example. Fundamentally, the design of the platform was based on the concept of DNA-mediated charge transport with the idea that DNA can behave like a wire, allowing electrons to flow through it and that the conductivity of that DNA wire is extremely sensitive to mistakes in the DNA itself.

The scientists started with two arrays of gold electrodes, one atop the other, embedded in Teflon blocks and separated by a thin spacer that formed a well for a solution. They attached strands of DNA to the lower electrodes, and then added the broken-down contents of a tissue sample to the solution well. After allowing time for any DNMT1 in the tissue sample to methylate the DNA, they added a restriction enzyme that severed the DNA if no methylation had occurred, and if DNMT1 was inactive. When they applied a current to the lower electrodes, the samples with DNMT1 activity passed the current clear through to the upper electrodes, where the activity could be measured.

Using the platform they measured DNMT1 activity in 10 pairs of human tissue samples, each composed of a colorectal tumor sample and an adjacent healthy tissue from the same patient. When they compared the samples within each pair, they consistently found significantly higher DNMT1 activity, hypermethylation, in the tumorous tissue. Notably, they found little correlation between the amount of DNMT1 in the samples and the presence of cancer; the correlation was with activity.

The authors concluded that DNMT1 hyperactivity as an indicator of cancerous transformation, measured electrochemically, is not clearly observed with the current standard techniques of DNMT1 analysis, including tritium labeling, reverse transcription quantitative polymerase chain reaction (RT-qPCR), and western blotting. Thus the electrochemical platform has the potential to provide a sensitive method of detecting DNMT1-related cancerous transformations, with greater reliability than current DNMT1 analysis techniques.

Jacqueline K. Barton, PhD, a professor of chemistry and senior author of the study, said, “The assay provides a reliable and sensitive measure of hypermethylation. It looks like hypermethylation is good indicator of tumorigenesis, so this technique could provide a useful route to early detection of cancer when hypermethylation is involved.” The study was published on June 25, 2015, in the journal Chemistry & Biology.

Related Links:

California Institute of Technology



New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.